As a supplement to its quarterly Outlook reports, Informa Pharma's Biomedtracker has taken a longer-term look at some key late-stage drugs projected to enter their first markets in 2019. These drugs represent new drug classes, major changes to standards of care, and large market opportunities, say Biomedtracker analysts in a new report, Key Potential Drug Launches In 2019.
Drugs that could be launched during 2019 could include Novartis AG's brolucizumab as a long-acting anti-VEGF therapy for wet...







